A Double-Blind Randomized Study of Clomipramine versus Maprotiline in Patients with Idiopathic Pain Syndromes
The DOI matches its Crossref record.
Abstract
Seventy patients with idiopathic syndromes were treated with maprotiline, a noradrenaline reuptake inhibitor, or clomipramine, a serotonin reuptake inhibitor in a 6-week, double-blind, randomized, multicenter trial. Fifty-two patients completed the double-blind phase. Overall, 50% of the patients improved. Significant decreases were seen not only in the levels of pain but also in bodily discomfort, sadness an inner tension (determined by visual analogue scales, VAS). A decrease was also found in the frequency of sleep disturbances, intellectual and emotional inhibition, irritability, guilt feelings, retardation, sadness and suicidal ideas (observed ratings). Sixty-three percent of the subjects showed an overall improvement during treatment with clomipramine as compared to 36% during treatment with maprotiline (p less than 0.05). During clomipramine treatment significant decreases were seen on all the six VAS: sadness, bodily discomfort, inner tension, concentration difficulties, memory disturbances and pain. Bodily discomfort and pain were significantly reduced during maprotiline treatment. The effects produced by clomipramine were also significantly greater than the effects caused by maprotiline as concerns psychic anxiety and inhibition (VAS). The overall reduction in VAS was significantly greater with clomipramine when compared to maprotiline. The most important side effects were dry mouth (both drugs) and sweating (clomipramine). However, in the clomipramine group, 8 patients were excluded due to side effects as compared to 1 patient in the maprotiline group. Thus, the results indicate that antidepressants reduce not only pain but are also of clinical value in the treatment of patients with idiopathic pain syndromes. Drugs with pronounced effects on the serotonin reuptake are to be preferred.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“EEG studies suggest that sleep length and efficiency are increased, and nocturnal disturbances reduced, for amitriptyline (Casper et al., 1994), clomipramine (Eberhard et al., 1988), trimipramine (Wolf et al., 2001), nortriptyline (Reynolds, III et al., 1997) and doxepin (Hajak et al., 1996)”
From Antidepressants and their effect on sleep (2005) · cites this paper as Eberhard et al., 1988
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Cited by
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Antidepressants for neuropathic pain
Saarto, T., & Wiffen, P. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005454.pub2 · Cited by 764
Onghena, P., & Van Houdenhove, B. (1992) · Pain · doi:10.1016/0304-3959(92)90144-z · Cited by 563
Antidepressants and their effect on sleep
Mayers, A. G., & Baldwin, D. S. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.726 · Cited by 323
“…in both groups (p < 0.001), but no sig between-group differences; HAMDS sig reduced for both groups (p value not specified), but no sig between groups differences Eberhard et al., 1988 25–150 mg Maprotiline 50–150 mg Depressed patients 52 6 weeks Sig improvement both groups sleep disturbance (p <…”
BackgroundInfluentialThe Irritable Bowel Syndrome: Review and a Graduated Multicomponent Treatment Approach
Drossman, D. A., & Thompson, W. G. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-12-1009 · Cited by 309
Venlafaxine treatment of fibromyalgia
Sayar, K., Aksu, G., Ak, I., & Tosun, M. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d112 · Cited by 157
Mianserin and chronic pain: a double-blind placebo-controlled process and outcome study
Onghena, P., De Cuyper, H., Van Houdenhove, B., & Verstraeten, D. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03439.x · Cited by 27
Metadata
- Authors
- Eberhard, G., von Knorring, L., Nilsson, H. L., Sundequist, U., Björling, G., Under, H., Svärd, K. O., & Tysk, L.
- Venue
- Neuropsychobiology
- Publisher
- S. Karger AG
- Published
- 1988
- Volume
- 19
- Issue
- 1
- Pages
- 25-34
- ISSN
- 0302-282X (ISSN-L)
- 1423-0224
- OpenAlex
- W2011941757
- Cited by
- 61
- References
- 0
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.